Autor: |
Gatell, JM, Assoumou, L, Stellbrink, HJ, Esser, S, Gras, J, Pozniak, AL, Vandekerckhove, L, Caluwe, E, De Wit, S, Necsoi, C, Florence, E, Van Frankenhuijsen, M, Raffi, F, Allavena, C, Reliquet, V, Cavellec, M, Rodallec, A, Le Tourneau, T, Connault, J, Molina, JM, Ferret, S, Previlon, M, Yazdanpanah, Y, Landman, R, Joly, V, Martinez, AP, Katlama, C, Caby, F, Ktorza, N, Schneider, L, Stephan, C, Wolf, T, Schuttfort, G, Rockstroh, J, Wasmuth, JC, Schwarze-Zander, C, Boesecke, C, Hoffmann, C, Sabranski, M, Jablonka, R, Wiehler, H, Behrens, G, Stoll, M, Ahrenstorf, G, Guaraldi, G, Nardini, G, Beghetto, B, Montforte, AD, Bini, T, Cogliandro, V, Di Pietro, M, Fusco, FM, Galli, M, Rusconi, S, Giacomelli, A, Meraviglia, P, Martinez, E, Gonzalez-Cordon, A, Torres, B, Domingo, P, Mateo, G, Gutierrez, M, Portillo, J, Merino, E, Reus, S, Boix, V, Masia, M, Gutierrez, F, Padilla, S, Clotet, B, Negredo, E, Bonjoch, A, Casado, JL, Banon-Escandell, S, Saban, J, Duque, A, Podzamczer, D, Saumoy, M, Acerete, L, Gonzalez-Garcia, J, Bernardino, JI, Arribas, JR, Hontanon, V, Moyle, G, Pagani, N, Bracchi, M, Vera, J, Clarke, A, Adams, T, Richardson, C, Winston, A, Mora-Peris, B, Mullaney, S, Waters, L, de Esteban, N, Milinkovic, A, Pett, S, Fox, J, Tiraboschi, JM, Johnson, M, Youle, M, Orkin, C, Rackstraw, S, Hand, J, Gompels, M, Jennings, L, Nicholls, J, Johnston, S, European Network AIDS Treatment |
Rok vydání: |
2019 |
Předmět: |
|
Zdroj: |
CLINICAL INFECTIOUS DISEASES r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname |
ISSN: |
1058-4838 |
Popis: |
Background. Both immediate and deferred switching from a ritonavir-boosted protease inhibitor (PI/r)-based regimen to a dolutegravir (DTG)-based regimen may improve lipid profile. Methods. European Network for AIDS Treatment 022 Study (NEAT022) is a European, open-label, randomized trial. Human immunodeficiency virus (HIV)-infected adults aged >= 50 years or with a Framingham score > 10% were eligible if HIV RNA was= 50 years old or with a Framingham score >= 10% was highly efficacious and well tolerated, and improved the lipid profile. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|